Seeking Alpha
16 Aug 2026, 12:15 UTC · 12w ago
Alamar Biosciences: Promising But Expensive Proteomics Growth
Impact · against what's priced in
Alamar Biosciences shows positive operational momentum through its recurring consumables model and TAM expansion into diagnostics. While growth is accelerating, the primary uncertainty remains the scalability of profitability as the installed base grows.
- ALMR+0.40
No priced-in read yet
- In context
The transition to a recurring revenue model via consumables growing faster than instrument sales, combined with a potential expansion into diagnostics, provides a path to higher margins and a larger addressable market.
Read from the article alone
Search tags
